Dobra cena.  w Internecie

szczegółowe informacje o produktach

Created with Pixso. Do domu Created with Pixso. produkty Created with Pixso.
Leki przeciwnowotworowe
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Nazwa marki: Boehringer Ingelheim
Numer modelu: Tabletki powlekane 18 mg
MOQ: 1 szt
Cena £: Please contact a specialist WhatsApp:55342706
Czas dostawy: Zbywalny
Warunki płatności: Western Union, Moneygram, t/t
Informacje szczegółowe
Miejsce pochodzenia:
USA
Orzecznictwo:
FDA NDA 218764
Specyfikacja:
18 mg*60 tabletek/pudełko
Wskazania:
Idiopatyczne zwłóknienie płuc, postępujące zwłóknienie płuc
Cel:
PDE4B
Nazwa produktu:
Nerandomilast
Polecić:
Należy stosować się do zaleceń lekarza
Składowanie:
Przechowywać w temperaturze od 20°C do 25°C, dopuszczając wahania temperatury otoczenia w zakresie o
Temperatura przechowywania:
20°C do 25°C
Zakres temperatur otoczenia:
15°C do 30°C
Formularz dawkowania:
Tabletka powlekana
Siła tabletu:
18 mg
Rozmiar opakowania:
60 tabletek/pudełko
Docelowy enzym:
PDE4B
Szczegóły pakowania:
Zbywalny
Możliwość Supply:
Zbywalny
Podkreślić:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Opis produktu
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.